http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2341306-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe13fb2387d38bc814cc82998153d301 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 |
| filingDate | 2007-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7b76c21df13ccac93b704adb79aabd1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38b7e9877358171b32d8b1211711c676 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45052b6a27ca5ebb5a5ec9eb5321c130 |
| publicationDate | 2008-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2341306-C1 |
| titleOfInvention | Method of oncological patients treatment |
| abstract | FIELD: medicine; oncology. n SUBSTANCE: laser diagnostics is preliminary applied. Finger tissues are tested for microcirculation index M 1 and oxygen saturation index OS 1 . Occlusive sample is taken. Oxygen saturation index OS 2 is evaluated directly before occlusive sample is completed. Maximum microcirculation index is evaluated after occlusive sample M 2 . Then introduction of 25-30 mg of Prednisolone solution is followed with introduction of Perftoran at 2.5-3.5 ml/kg of patient weight. In 1-1.5 hours finger tissues are re-tested for microcirculation index M3 and oxygen saturation index OS 3 . Occlusive sample is taken. Oxygen saturation index OS 4 is evaluated directly before occlusive sample is completed. Maximum microcirculation index is evaluated after occlusive test M 4 . If ratio value is within , session of radiation therapy is applied. Method allows for evaluation of tissues and bodies microcirculation, of tissue hypoxia and the most reasonable time of radiation therapy following introduction of Perftoran. n EFFECT: higher regress of tumour processes. n 2 cl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2550663-C2 |
| priorityDate | 2007-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.